LEADER 02782nam 22006374a 450 001 9910450049303321 005 20200520144314.0 010 $a0-8147-5290-X 010 $a0-8147-6502-5 035 $a(CKB)1000000000005643 035 $a(EBL)865771 035 $a(OCoLC)779828238 035 $a(SSID)ssj0000282392 035 $a(PQKBManifestationID)11194846 035 $a(PQKBTitleCode)TC0000282392 035 $a(PQKBWorkID)10323029 035 $a(PQKB)11180138 035 $a(MiAaPQ)EBC865771 035 $a(OCoLC)54759695 035 $a(MdBmJHUP)muse10533 035 $a(Au-PeEL)EBL865771 035 $a(CaPaEBR)ebr10032526 035 $a(EXLCZ)991000000000005643 100 $a20001016d2001 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aNothing but the truth$b[electronic resource] $ewhy trial lawyers don't, can't, and shouldn't have to tell the whole truth /$fSteven Lubet 210 $aNew York $cNew York University Press$dc2001 215 $a1 online resource (231 p.) 225 1 $aCritical America 300 $aDescription based upon print version of record. 311 $a0-8147-5174-1 311 $a0-8147-5173-3 320 $aIncludes bibliographical references and index. 327 $aBiff and me : stories that are truer than true -- Edgardo Mortara : forbidden truths -- John Brown : political truth and consequences -- Wyatt Earp : truth and context -- Liberty Valance : truth or justice -- Atticus Finch : race, class, gender, and truth -- Sheila McGough : the impossibility of the whole truth. 330 $aLubet's Nothing But The Truth presents a novel and engaging analysis of the role of storytelling in trial advocacy. The best lawyers are storytellers, he explains, who take the raw and disjointed observations of witnesses and transform them into coherent and persuasive narratives. Critics of the adversary system, of course, have little patience for storytelling, regarding trial lawyers as flimflam artists who use sly means and cunning rhetoric to befuddle witnesses and bamboozle juries. Why not simply allow the witnesses to speak their minds, without the distorting influence of lawyers' strata 410 0$aCritical America. 606 $aLaw$zUnited States 606 $aTrial practice$zUnited States 606 $aTruthfulness and falsehood 608 $aElectronic books. 615 0$aLaw 615 0$aTrial practice 615 0$aTruthfulness and falsehood. 676 $a347.73/75 700 $aLubet$b Steven$0848027 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910450049303321 996 $aNothing but the truth$92480459 997 $aUNINA LEADER 05395nam 2200673Ia 450 001 9910877382003321 005 20230617021407.0 010 $a1-280-52024-8 010 $a9786610520244 010 $a3-527-60515-0 010 $a3-527-60147-3 035 $a(CKB)1000000000019314 035 $a(EBL)481275 035 $a(SSID)ssj0000141534 035 $a(PQKBManifestationID)11147200 035 $a(PQKBTitleCode)TC0000141534 035 $a(PQKBWorkID)10090060 035 $a(PQKB)11289588 035 $a(MiAaPQ)EBC481275 035 $a(OCoLC)55689617 035 $a(EXLCZ)991000000000019314 100 $a20021028d2003 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug bioavailability $eestimation of solubility, permeability, absorption and bioavailability /$fedited by Han van de Waterbeemd, Hans Lennerna?s and Per Artursson 210 $aWeinheim $cWiley-VCH$dc2003 215 $a1 online resource (605 p.) 225 1 $aMethods and principles in medicinal chemistry ;$vv. 18 300 $aDescription based upon print version of record. 311 $a3-527-30438-X 320 $aIncludes bibliographical references and index. 327 $aDrug Bioavailability Estimation of Solubility, Permeability, Absorption and Bioavailability; Contents; Preface; Foreword; List of Authors; I Studies of Membrane Permeability and Oral Absorption; 1 Physico-chemical Approaches to Drug Absorption; Abbreviations; Symbols; 1.1 Introduction; 1.2 Drug-like Properties; 1.3 Dissolution and Solubility; 1.3.1 Calculated Solubility; 1.4 Ionization (pK(a)); 1.5 Lipophilicity; 1.5.1 Calculated log P; 1.6 Molecular Size and Shape; 1.6.1 Calculated Size Descriptors; 1.7 Hydrogen Bonding; 1.7.1 Calculated Hydrogen-Bonding Descriptors; 1.8 Amphiphilicity 327 $a1.9 Permeability1.9.1 Artificial Membranes; 1.9.2 IAM, ILC, MEKC, and BMC; 1.9.3 Liposome Partitioning; 1.9.4 Biosensors; 1.9.5 Ghost Erythrocytes and Diffusion Constants; References; 2 High-throughput Measurement of log D and pK(a); Abbreviations; Symbols; 2.1 Introduction; 2.2 Relationship between Ionization and Lipophilicity; 2.3 Measuring log D; 2.3.1 Shake-flask Method; 2.3.2 pH-metric Method; 2.3.3 Direct Chromatographic Methods; 2.3.3.1 Chromatographic Hydrophobicity Index (CHI); 2.3.3.2 Microemulsion Electrokinetic Chromatography (MEEKC) 327 $a2.3.3.3 Chromatography in the Presence of Octanol2.3.3.4 Reversed-Phase Chromatography; 2.3.3.5 Liquid-Liquid Partition Chromatography; 2.4 Measuring pK(a); 2.4.1 Review of Methods; 2.4.2 The Effect of Co-solvents on pK(a); 2.4.3 pH-Metric Titration; 2.4.4 Hybrid pH-Metric/UV Method; 2.4.5 Other Methods; 2.4.6 pH Gradient Titration; 2.5 Some Thoughts about High-throughput Analytical Chemistry; Acknowledgments; References; 3 High-throughput Measurement of Permeability Profiles; Abbreviations; Symbols; 3.1 Introduction 327 $a3.2 Key Historical Developments in Artificial-Membrane Permeability Measurement3.3 The Ideal in vitro Artificial Membrane Permeability Model; 3.3.1 Lipid Compositions in Biological Membranes; 3.3.2 Permeability-pH Considerations; 3.3.3 Role of Serum Proteins; 3.3.4 Effects of Cosolvents, Bile Acids, and other Surfactants; 3.3.5 Components of the Ideal; 3.4 New Directions in PAMPA; 3.4.1 Concentrated and Charged Phospholipid Membranes; 3.4.2 Gradient-pH Permeability Equation; 3.4.3 Permeability Measurements: High-phospholipid in Surfactant-free Solutions 327 $a3.4.4 Membrane Retention Measurements: High-phospholipid in Surfactant-free Solutions3.4.5 Egg Lecithin and the Degree of Negative Charge; 3.4.6 Summary: Increasing Phospholipid Content in the Absence of Sink Conditions; 3.4.7 Effects of Surfactant on High-phospholipid Membrane Permeability and Retention; 3.4.8 Quality and Usefulness of the UV Spectra; 3.4.9 Iso-pH and Gradient-pH Mapping in 2% DOPC-Dodecane; 3.4.10 Iso-pH Mapping in 20% Soy Lecithin-Dodecane, with Surfactant 327 $a3.4.11 Predictions of in vivo Human Jejunal Permeabilities using the Improved 20% Soy Lecithin with Surfactant in vitro PAMPA Technique 330 $aThe peroral application (swallowing) of a medicine means that the body must first resorb the active substance before it can begin to take effect. The efficacy of drug uptake depends on the one hand on the chemical characteristics of the active substance, above all on its solubility and membrane permeability. On the other hand, it is determined by the organism's ability to absorb pharmaceuticals by way of specific transport proteins or to excrete them. Since many pharmacologically active substances are poorly suited for oral intake, a decisive criterion for the efficacy of a medicine is its so- 410 0$aMethods and principles in medicinal chemistry ;$vv. 18. 606 $aDrugs$xBioavailability 606 $aDrugs$xSolubility 615 0$aDrugs$xBioavailability. 615 0$aDrugs$xSolubility. 676 $a615.1 676 $a615.19 676 $a615/.7 701 $aWaterbeemd$b Han van de$0860600 701 $aLennerna?s$b Hans$01763943 701 $aArtursson$b Per$01763944 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910877382003321 996 $aDrug bioavailability$94204632 997 $aUNINA